Evozyne, LLC, a molecular engineering technology company, entered a strategic collaboration and license agreement with Takeda Pharmaceutical Co. Ltd. under which Evozyne’s evolution-based protein design technology will be used to research and develop proteins that could be incorporated into next generation gene therapies for genetic disorders within inborn errors of metabolism and lysosomal storage disease areas. Evozyne leverages advanced computational and machine learning methods in i...